ADAP Advocacy Urges HIV Medication Carve-Out in Medicare Drug Price Negotiations

ADAP Advocacy has publicly commented on the Centers for Medicare and Medicaid Services' proposed guidance for the Medicare Drug Price Negotiation Program, advocating for a carve-out for HIV antiretroviral therapies. The organization warns that including HIV medications in the Negotiation Program could endanger the lives of People Living with HIV/AIDS (PLWHA) by potentially limiting their access to essential treatments. Brandon M. Macsata, CEO of ADAP Advocacy, emphasized the critical importance of maintaining access to HIV medications to prevent health complications and new infections, underscoring the 'treatment as prevention' approach's role in the fight against HIV.

The public comments submitted by ADAP Advocacy to CMS outline the potential consequences of negotiating prices for HIV medications, including the risk of patients falling out of treatment and developing resistance to medications. The organization's stance is rooted in the belief that ensuring uninterrupted access to HIV treatments is vital for the health of PLWHA and the broader public health effort to control the HIV epidemic. For more details on ADAP Advocacy's position, refer to their written testimony to CMS.